Novel free-paclitaxel-loaded redox-responsive nanoparticles based on a disulfide-linked poly(ethylene glycol)-drug conjugate for intracellular drug delivery: synthesis, characterization, and antitumor activity in vitro and in vivo.

To address the obstacles facing cancer chemotherapeutics, including toxicity, side effects, water insolubility, and lack of tumor selectivity, a novel stimuli-responsive drug-delivery system was developed based on paclitaxel-loaded poly(ethylene glycol)-disulfide-paclitaxel conjugate nanoparticles (PEG-SS-PTX/PTX NPs). The formulation emphasizes several benefits, including polymer-drug conjugates/prodrugs, self-assembled NPs, high drug content, redox responsiveness, and programmed drug release. The PTX-loaded, self-assembled NPs, with a uniform size of 103 nm, characterized by DLS, TEM, XRD, DSC, and (1)H NMR, exhibited excellent drug-loading capacity (15.7%) and entrapment efficiency (93.3%). PEG-SS-PTX/PTX NPs were relatively stable under normal conditions but disassembled quickly under reductive conditions, as indicated by their triggered-aggregation phenomena and drug-release profile in the presence of dithiothreitol (DTT), a reducing agent. Additionally, by taking advantage of the difference in the drug-release rates between physically loaded and chemically conjugated drugs, a programmed drug-release phenomenon was observed, which was attributed to a higher concentration and longer action time of the drugs. The influence of PEG-SS-PTX/PTX NPs on in vitro cytotoxicity, cell cycle progression, and cellular apoptosis was determined in the MCF-7 cell line, and the NPs demonstrated a superior anti-proliferative activity associated with PTX-induced cell cycle arrest in G2/M phase and apoptosis compared to their nonresponsive counterparts. Moreover, the redox-responsive NPs were more efficacious than both free PTX and the non-redox-responsive formulation at equivalent doses of PTX in a breast cancer xenograft mouse model. This redox-responsive PTX drug delivery system is promising and can be explored for use in effective intracellular drug delivery.

[1]  Xing Guo,et al.  pH-triggered intracellular release from actively targeting polymer micelles. , 2013, Biomaterials.

[2]  H. S. Oh,et al.  In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[3]  James B. Mitchell,et al.  Noninvasive imaging of tumor redox status and its modification by tissue glutathione levels. , 2002, Cancer research.

[4]  Mingqiang Zhu,et al.  Heparin-paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity. , 2009, Bioconjugate chemistry.

[5]  L. Gerweck,et al.  Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics , 2006, Molecular Cancer Therapeutics.

[6]  Shufeng Zhou,et al.  Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[7]  Hao Bai,et al.  Effect of molecular weight of PGG-paclitaxel conjugates on in vitro and in vivo efficacy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[8]  F. Meng,et al.  Biodegradable micelles with sheddable poly(ethylene glycol) shells for triggered intracellular release of doxorubicin. , 2009, Biomaterials.

[9]  Yi Wang,et al.  Actively targeted delivery of anticancer drug to tumor cells by redox-responsive star-shaped micelles. , 2014, Biomaterials.

[10]  Gert Storm,et al.  Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.

[11]  Jesse V Jokerst,et al.  Nanoparticle PEGylation for imaging and therapy. , 2011, Nanomedicine.

[12]  M. Maeda,et al.  A polymer micelle responding to the protein kinase a signal , 2001 .

[13]  Tingyun Yang,et al.  Novel cathepsin B-sensitive paclitaxel conjugate: Higher water solubility, better efficacy and lower toxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Tsao,et al.  Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. , 2000, Cancer research.

[15]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .

[16]  Yoshio Hayashi,et al.  Paclitaxel prodrugs: toward smarter delivery of anticancer agents. , 2006, Journal of medicinal chemistry.

[17]  Ruth Duncan,et al.  Polymer conjugates as anticancer nanomedicines , 2006, Nature Reviews Cancer.

[18]  Lei Yu,et al.  Synthesis, characterization, and biological evaluation of poly(L-γ-glutamyl-glutamine)- paclitaxel nanoconjugate , 2010, International journal of nanomedicine.

[19]  Qiang Zhang,et al.  Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Chun Xing Li,et al.  Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate. , 1998, Cancer research.

[21]  Dong Yang,et al.  Preparation of copolymer paclitaxel covalently linked via a disulfide bond and its application on controlled drug delivery. , 2012, The journal of physical chemistry. B.

[22]  Jianping Zhou,et al.  Redox-sensitive micelles self-assembled from amphiphilic hyaluronic acid-deoxycholic acid conjugates for targeted intracellular delivery of paclitaxel. , 2012, Biomaterials.

[23]  J. Gliński,et al.  Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. , 1989, Journal of medicinal chemistry.

[24]  Sung Eun Kim,et al.  Disulfide-cross-linked PEG-poly(amino acid)s copolymer micelles for glutathione-mediated intracellular drug delivery. , 2008, Chemical communications.

[25]  Patrick Soon-Shiong,et al.  Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[26]  Gianfranco Pasut,et al.  PEG conjugates in clinical development or use as anticancer agents: an overview. , 2009, Advanced drug delivery reviews.

[27]  V. Torchilin,et al.  Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety , 2013, Proceedings of the National Academy of Sciences.

[28]  Hongfan Sun,et al.  Paclitaxel-loaded polymeric micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation. , 2012, Nanomedicine : nanotechnology, biology, and medicine.

[29]  Sung-Bae Kim,et al.  Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer , 2008, Breast Cancer Research and Treatment.

[30]  Martin Werle,et al.  Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[31]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Kannan,et al.  Dendrimer-drug conjugates for tailored intracellular drug release based on glutathione levels. , 2008, Bioconjugate chemistry.

[33]  Qiang Zhang,et al.  A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. , 2012, Molecular pharmaceutics.

[34]  Kinam Park,et al.  Hydrotropic polymer micelle system for delivery of paclitaxel. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[35]  V. Torchilin,et al.  Structure and design of polymeric surfactant-based drug delivery systems. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Cao Xie,et al.  Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Jingxue Shi,et al.  The promise of paclitaxel-peptide conjugates for MMP-2-targeted drug delivery , 2010, Cancer biology & therapy.

[38]  J. M. Harris,et al.  Effect of pegylation on pharmaceuticals , 2003, Nature Reviews Drug Discovery.

[39]  Lei Yu,et al.  Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)–paclitaxel nanoparticles , 2011, International journal of nanomedicine.

[40]  P. Ho,et al.  A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. , 2010, Biomaterials.

[41]  J. Beijnen,et al.  Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer. , 1998, Anti-cancer drugs.

[42]  Jean-Christophe Leroux,et al.  Disulfide-containing parenteral delivery systems and their redox-biological fate. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[43]  Jijin Gu,et al.  Integrin-facilitated transcytosis for enhanced penetration of advanced gliomas by poly(trimethylene carbonate)-based nanoparticles encapsulating paclitaxel. , 2013, Biomaterials.

[44]  Lei Yu,et al.  Physicochemical properties and biocompatibility of a polymer-paclitaxel conjugate for cancer treatment , 2011, International journal of nanomedicine.

[45]  N. Rapoport.  Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery , 2007 .

[46]  Li Wang,et al.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. , 2009, Biomaterials.

[47]  P. Chang,et al.  Fabrication and reduction-sensitive behavior of polyion complex nano-micelles based on PEG-conjugated polymer containing disulfide bonds as a potential carrier of anti-tumor paclitaxel. , 2013, Colloids and surfaces. B, Biointerfaces.

[48]  Shyh-Dar Li,et al.  A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[49]  Zhiyuan Zhong,et al.  Glutathione-responsive nano-vehicles as a promising platform for targeted intracellular drug and gene delivery. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[50]  E K Rowinsky,et al.  Paclitaxel (taxol) , 1995, The New England journal of medicine.

[51]  Julie Mougin,et al.  Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery. , 2013, Bioconjugate chemistry.

[52]  A. Bernkop‐Schnürch,et al.  Polymers with Thiol Groups: A New Generation of Mucoadhesive Polymers? , 1999, Pharmaceutical Research.

[53]  Young Jik Kwon,et al.  Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. , 2012, Advanced drug delivery reviews.

[54]  Liandong Deng,et al.  Sustained release of PTX-incorporated nanoparticles synergized by burst release of DOX⋅HCl from thermosensitive modified PEG/PCL hydrogel to improve anti-tumor efficiency. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[55]  Jinming Gao,et al.  Multicolored pH-tunable and activatable fluorescence nanoplatform responsive to physiologic pH stimuli. , 2012, Journal of the American Chemical Society.

[56]  Qiang Zhang,et al.  Free paclitaxel loaded PEGylated-paclitaxel nanoparticles: preparation and comparison with other paclitaxel systems in vitro and in vivo. , 2014, International journal of pharmaceutics.

[57]  F. Dosio,et al.  Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. , 2012, International journal of pharmaceutics.

[58]  C. Contag,et al.  Overcoming multidrug resistance of small-molecule therapeutics through conjugation with releasable octaarginine transporters , 2008, Proceedings of the National Academy of Sciences.

[59]  J. Burroughs,et al.  Overview of Taxol safety. , 1993, Journal of the National Cancer Institute. Monographs.

[60]  Michael Hawkins,et al.  Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol) , 2005, Clinical Cancer Research.

[61]  Peisheng Xu,et al.  Redox Potential Ultrasensitive Nanoparticle for the Targeted Delivery of Camptothecin to HER2-Positive Cancer Cells , 2014, Molecular pharmaceutics.